CSG SYSTEMS INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CSG SYSTEMS INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $260.49M | Feb 19, 2021 |
| FY2020 | Sep 30, 2020 | $244.11M | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | $240.32M | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | $245.62M | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | $254.75M | Feb 19, 2021 |
| FY2020 | Sep 30, 2019 | $251.41M | Feb 19, 2021 |
| FY2020 | Jun 30, 2019 | $245.86M | Feb 19, 2021 |
| FY2020 | Mar 31, 2019 | $244.79M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $247.27M | Feb 21, 2020 |
| FY2019 | Sep 30, 2018 | $213.06M | Feb 21, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.20B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.17B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.09B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $990.53M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $996.81M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $875.06M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $789.58M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $760.96M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.88M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $86.85M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $66.25M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $44.06M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $72.33M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $58.71M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $82.77M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $66.13M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $61.36M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $62.88M | Feb 22, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.75M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $131.33M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $123.88M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $78.75M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $124.19M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $23.68M | Feb 19, 2021 |
| FY2020 | Sep 30, 2020 | $28.95M | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | $19.78M | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | $33.16M | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | $30.26M | Feb 19, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.57M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $158.19M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $143.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $137.91M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $134.69M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $122.85M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $127.99M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $124.03M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $113.22M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $98.68M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $281.48M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $258.31M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $247.61M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $238.02M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $214.69M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $198.28M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $191.33M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $169.31M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $153.70M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $140.47M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.94M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $135.72M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $131.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $63.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $140.22M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $172.99M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $151.04M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $143.34M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $127.20M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $84.19M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.55M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $22.42M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $27.98M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $36.99M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $26.56M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $29.40M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $37.32M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $57.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $28.94M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $14.26M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.50B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.44B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.35B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.39B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.33B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.28B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.11B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $904.53M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $891.88M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.22B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.17B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $993.30M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $946.91M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $909.61M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $886.37M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $753.34M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $561.79M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $600.68M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $355.25M | Feb 17, 2023 |
| FY2022 | Dec 31, 2021 | $436.61M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $422.40M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $396.66M | Feb 19, 2021 |
| FY2020 | Dec 31, 2018 | $361.02M | Feb 19, 2021 |
| FY2020 | Dec 31, 2017 | $342.75M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $251.36M | Feb 21, 2020 |
| FY2018 | Dec 31, 2015 | $345.85M | Feb 22, 2019 |
| FY2017 | Dec 31, 2014 | $358.63M | Feb 23, 2018 |
| FY2016 | Dec 31, 2013 | $358.26M | Feb 24, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $324.71M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $316.04M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $308.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $304.04M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $321.33M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $272.32M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $259.16M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $255.82M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $210.08M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $201.09M | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $968.13M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $936.22M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $916.06M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $876.40M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $848.62M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $795.13M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $749.44M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $714.85M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.01M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $161.79M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $186.26M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $150.37M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $205.64M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $188.70M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $156.55M | Feb 18, 2022 |
| FY2019 | Dec 31, 2018 | $139.28M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $122.24M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $126.35M | Feb 23, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $539.45M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $538.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $542.50M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $412.97M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $374.72M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $351.22M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $356.82M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $359.83M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $331.74M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $376.42M | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 19, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 19, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.37M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 28.85M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 29.54M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 31.27M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 32.50M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | 32.71M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 32.89M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 33.16M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 33.52M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 32.26M | Feb 23, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $14.50M | Feb 28, 2014 |